

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2713119

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS (FIRST LIEN)
CONVEYING PARTY DATA	
Name	Execution Date
MORGAN STANLEY SENIOR FUNDING, INC.	02/04/2014
RECEIVING PARTY DATA	
Name:	ALKERMES, INC.
Street Address:	852 WINTER STREET
City:	WALTHAM
State/Country:	MASSACHUSETTS
Postal Code:	02451
Name:	ALKERMES PHARMA IRELAND LIMITED
Street Address:	MONSKLAND
City:	ATHLONE CO. WESTMEATH
State/Country:	IRELAND
PROPERTY NUMBERS Total: 7	
Property Type	Number
Application Number:	11520058
Patent Number:	8338427
Patent Number:	8338428
Patent Number:	6987111
Patent Number:	7658998
Application Number:	13648544
Application Number:	12241404
CORRESPONDENCE DATA	
Fax Number:	(650)838-5109

Phone: 650-838-3743
Email: JLIK@SHEARMAN.COM
Correspondence will be sent via US Mail when the email attempt is unsuccessful.
Correspondent Name: ZHENG BAO
Address Line 1: 3000 EL CAMINO REAL, 6TH FLOOR
Address Line 2: SHEARMAN & STERLING LLP
Address Line 4: PALO ALTO, CALIFORNIA 94306

ATTORNEY DOCKET NUMBER:	35613-12286
-------------------------	-------------

NAME OF SUBMITTER:	ZHENG BAO
--------------------	-----------

Signature:	/ZHENG BAO/
------------	-------------

Date:	02/04/2014
-------	------------

Total Attachments: 4 source=0 - Patent Termination and Release#page1.tif source=0 - Patent Termination and Release#page2.tif source=0 - Patent Termination and Release#page3.tif source=0 - Patent Termination and Release#page4.tif
--

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN PATENTS (FIRST LIEN)**

This Termination and Release of Security Interest in Patents (this "**Release**") is granted on this 4th day of February, 2014, effective April 1, 2013 (the "**Effective Date**"), by Morgan Stanley Senior Funding, Inc. ("**Morgan Stanley**"), as collateral agent for the Secured Parties under the security agreements referenced below, in favor of Alkermes, Inc., a corporation organized under the laws of the Commonwealth of Pennsylvania, located at 852 Winter Street, Waltham, Massachusetts ("**Alkermes**" or the "**Borrower**") and Alkermes Pharma Ireland Limited, a private limited company organized under the laws of the Republic of Ireland (registered number 448848) ("**APIL**"), with respect to the Disposed Patents (as defined below).

W I T N E S S E T H :

WHEREAS, Borrower, APIL, the other parties thereto and Morgan Stanley are party to a First Lien Guarantee and Collateral Agreement dated as of September 16, 2011, and amended on September 25, 2012, in favor of Morgan Stanley (the "**Collateral Agreement**");

WHEREAS, pursuant to the Collateral Agreement, on September 16, 2011, Morgan Stanley, as collateral agent, Borrower and APIL entered into a Patent Security Agreement, which was thereafter recorded with the U.S. Patent and Trademark Office (the "**USPTO**") on September 29, 2011 at Reel/Frame 026994/0186 (the "**Patent Security Agreement**");

WHEREAS, pursuant to the Patent Security Agreement, Morgan Stanley received security interests in all of Borrower's and APIL's respective rights, titles and interests in the United States and throughout the world in the Patent Collateral (as this term is defined in the Patent Security Agreement), including, without limitation, those patents and patent applications set forth on Schedule A hereto (such patents and applications on Schedule A, the "**Disposed Patents**"); and

WHEREAS, Morgan Stanley desires to release, as of the Effective Date, any and all security interests, and any other lien, it has in the Disposed Patents to Alkermes and APIL, as applicable.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Morgan Stanley hereby agrees as follows:

1. As of the Effective Date, Morgan Stanley hereby releases, terminates and discharges, without representation, recourse or warranty whatsoever, each security interest in the Disposed Patents that was granted to Morgan Stanley under the Patent Security Agreement. Morgan Stanley acknowledges and agrees that the Patent Security Agreement has been terminated solely with respect to the


Disposed Patents. Other than the foregoing release of the Disposed Patents, Morgan Stanley hereby confirms its lien on, and security interest in, all right, title and interest in and to all other Patent Collateral currently pledged to it under the Patent Security Agreement.

2. The parties hereto authorize and request the Commissioner of Patents and Trademarks of the United States of America to record this Release against the Disposed Patents. Morgan Stanley agrees, at the Borrower's expense, to perform all further acts and execute and deliver all further documents and/or instruments that may be reasonably necessary to carry out the provisions of this Release.
3. This Release is effective as of the Effective Date.
4. This Release shall be governed by and construed in accordance with the law of the State of New York.
5. This Release shall be binding upon Morgan Stanley's representatives, successors, assigns and transferees, and is made in favor of and for the benefit of Borrowers, APIL and their respective successors and assigns.

[Remainder of Page Intentionally Blank]

IN WITNESS WHEREOF, the undersigned has caused this Release to be executed by its duly authorized representatives as of the date first above written.

MORGAN STANLEY SENIOR FUNDING, INC.

By 
Name: STEPHEN B. KRANE
Title: VP
Date: _____

Patent Release - Signature Page

PATENT
REEL: 032161 FRAME: 0479

SCHEDULE A

<u>Patent</u>	<u>Reg./App. No.</u>	<u>Reg./App. Date</u>
NANOPARTICULATE ARIPIRAZOLE FORMULATIONS	11/520058	9/13/2006
METHODS FOR ADMINISTERING ARIPIRAZOLE	8338427	12/25/2012
METHODS FOR ADMINISTERING ARIPIRAZOLE	8338428	12/25/2012
ARIPIRAZOLE, GLANZAPINE AND HALOPERIDOL PAMOATE SALTS	6987111	1/17/2006
METHOD OF PREPARING SUSTAINED RELEASE MICROPARTICLES	7658998	2/9/2010
METHODS FOR ADMINISTERING ARIPIRAZOLE	13/648544	10/10/2012
METHODS FOR ADMINISTERING ACTIVE AGENTS TO CYP3A4 SENSITIVE PATIENTS	12/241404	9/30/2008

Schedule A